Anson, Matthew
Zhao, Sizheng S.
Austin, Philip
Ibarburu, Gema H.
Malik, Rayaz A.
Alam, Uazman
Article History
Received: 20 March 2023
Accepted: 6 June 2023
First Online: 28 July 2023
Data availability
: To gain access to the data in the TriNetX research network, a request can be made to TriNetX (ExternalRef removed), but costs may be incurred, a data sharing agreement would be necessary and no patient identifiable information can be obtained. No data from Liverpool University NHS Foundation Trust were utilised in this analysis.
: This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.
: PA and GHI are employees of TriNetX LLC. RAM reports honoraria from Eli Lilly, Novo Nordisk, Sanofi Aventis and Procter & Gamble for educational meetings and funding for investigator-initiated studies from Procter & Gamble and Pfizer. UA has received honoraria from Procter & Gamble, Viatris, Grunenthal and Sanofi for educational meetings. UA has also received investigator-led funding by Procter & Gamble. All other authors declare that there are no relationships or activities that might bias, or be perceived to bias, their contribution to this manuscript.
: MA contributed to the generation of the results and analysis using the TriNetX platform and took the lead on writing the manuscript. PA and GHI facilitated access to the TriNetX platform and assisted in generating the results and analysis. PA and GHI also contributed to the writing of the manuscript. SSZ and RAM provided senior author input in the design of the study and review of the manuscript, and UA oversaw the study development, manuscript writing, provided senior author review of the manuscript and is the guarantor of this work. All authors approved the final manuscript.